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Keeping NF-κB in check
NF-κB, a central proinflammatory regulator, 
gets activated by TNF receptor–associated factors 
(TRAFs). But He et al. (page 2413) now report 
that one TRAF family member (TRAF3) instead 
negatively regulates an alternative NF-κB 
activation pathway.
Classical activation of NF-κB occurs by TRAF-
controlled degradation of cytoplasmic inhibitory 
binding proteins, which leads to nuclear accumulation of the p50 forms 
of NF-κB. Activation can also occur by a recently discovered route 
requiring NF-κB–inducing kinase (NIK), which releases a different 
NF-κB complex, thus one containing p52.
It was known that, unlike other TRAFs, overexpression of TRAF3 
does not induce the classical NF-κB pathway. By examining TRAF3-
null mice (which die soon after birth), He et al. now show that cells from 
these mice have constitutively active noncanonical p52 NF-κB. This 
constitutive activation was associated with aberrant accumulation of NIK 
protein, but not mRNA, suggesting that TRAF3 blocks noncanonical 
NF-κB by reducing NIK protein stability.
Crossing the TRAF3−/− mice with mice that lacked p52 prevented 
their early death, showing that overactivity of p52 was, indeed, the 
cause of lethality. The final cause of death in TRAF3−/− mice is 
uncertain but is most likely due to over-inflammation caused by the 
unfettered activation of NF-κB-signaling. 
Controlling clots with Clk1
Platelets are critical blood cells involved in clotting. An early step in clot 
construction requires tissue factor (TF), but whether platelets make TF was 
unknown. New work by Schwertz et al. (page 2433) reveals that these nuclei-
free cells doproduce TF by cytoplasmic splicing and further identify the 
kinase Clk1 as a splicing activator.
After injury to a blood vessel, platelets are the first cells on the scene to 
plug the hole. Platelets get activated by attachment to exposed collagen 
(amongst other things), and promote a TF-dependent coagulation cascade 
on their cell membranes. This ultimately results in large-scale fibrin 
production and the assembly of a tough fibrin meshwork over the platelet 
plug. TF is released from the injured tissue, but whether platelets themselves 
express TF is a debated question.
Schwertz et al. found that activated human platelets contained TF mRNA. 
Resting platelets instead contained unspliced TF pre-mRNA. Activation, the team 
showed, induced splicing and subsequent translation of TF in as little as 5 min.
Cytoplasmic splicing was described for the first time by this group a year 
ago. The precise mechanism is unknown, but splicing factor SF2/ASF was 
identified in platelet cytoplasms. In nucleated cells, Clk1 activates SF2/ASF 
by phosphorylation. Interrupting this modification, the team now shows, 
prevents processing of TF pre-mRNA.
A number of conditions lead to increased blood clotting. In recent 
unpublished work, the team found that platelets isolated from septic 
patients, in whom thrombosis occurs, are more prone to clotting and contain 
increased levels of spliced TF mRNA. Clk1-controlled splicing might thus be a 
good target for anticoagulation treatments. 
Curtailing infection
Certain crafty viruses can cause the host’s 
immune system to suppress itself, and thereby 
establish persistent chronic infection. But 
Ejrnaes et al. (page 2461) and Brooks et al. 
(Nat. Med. doi:10.1038/nm1492) have now 
found that suppressing the suppressor, which 
they show is the cytokine IL-10, can fight 
persistent infection.
IL-10 is known to exert a suppressive 
effect on cells of the immune system, includ-
ing T cells and antigen-presenting cells, and 
elevated levels of IL-10 have been observed 
during persistent infection with hepatitis C 
virus, human immunodeficiency virus, and 
Epstein-Barr virus.
Now, both teams have observed that mice 
lacking IL-10 are resistant to persistent infec-
tion with lymphocytic choriomeningitis virus 
(LCMV). They also show that normal mice 
infected with LCMV have increased IL-10 
production and decreased numbers of virus-
killing CD8+ T cells. Ejrnaes et al. show that 
treating LCMV-infected mice with antibody 
that blocks the IL-10 receptor restored these 
antiviral CD8+ T cells and resulted in low or 
undetectable viral load, less weight loss and 
healthier coats. Importantly, the same reversal of 
symptoms and eradication of virus was achieved 
if treatment was administered later in infection.
Blocking the action of IL-10 might, there-
fore, be a potential therapy for human cases of 
persistent viral infection. Prolonged treatment 
with a potent stimulator of the immune system, 
however, might lead to undesirable auto immune 
conditions, explains Matthias von Herrath, who 
led the study published here. His team is thus 
looking into the use of shorter and lower dose 
IL-10 treatments in combination with vaccines 
against virus-specific antigens. 
Cells lacking TRAF3 
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Mice with suppressed IL-10 action (right) eradicate 
persistent viral infection and improve their health.